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Abstract
Introduction: Immediate-type hypersensitivity to glucocorticosteroids is rare but well known
among allergists. Surprisingly, very few reports of glucocorticosteroid hypersensitivity in children
exist although glucocorticosteroid treatment is particularly common in this age group.
Case presentation: We report the case of a 2-year-old boy who developed generalized urticaria,
facial angio-oedema, nausea and severe dyspnoea after intravenous application of prednisolone-21-
hydrogen succinate. Skin prick testing with prednisolone-21-hydrogen succinate elicited a positive
result; no reactions were observed to prednisone, betamethasone or dexamethasone. While
fluorescence enzyme immunoassay analysis revealed no specific IgE antibodies against
prednisolone-21-hydrogen succinate, CD63-based basophil activation testing with the culprit drug
prednisolone-21-hydrogen succinate was positive. In contrast, additional incubation of basophils
with prednisone, betamethasone and dexamethasone did not elicit any significant response. Hence,
we performed an oral provocation test with betamethasone and a titrated intravenous
dexamethasone challenge. As both drugs were tolerated without any complications they were
recommended for future treatment.
Conclusion: In a child with confirmed immediate-type hypersensitivity to glucocorticosteroids, it
is still not possible to predict which glucocorticosteroid might be tolerated by solely relying on
clinical history or results of skin and in vitro testing. Therefore, incremental glucocorticosteroid
challenges under standardized clinical conditions remain necessary in order to facilitate a patient-
tailored emergency treatment and to avoid severe reactions to glucocorticosteroids in these
patients.
Introduction
Immediate-type hypersensitivity to glucocorticosteroids
(GCs) is rare but has been well known among allergists
since the introduction of these agents in the early 1950s.
To date, approximately 100 clinical cases of GC hypersen-
sitivity have been published with a majority of patients
being adults suffering from anaphylactic symptoms
within several minutes of oral or intravenous GC applica-
tion [1]. Surprisingly, very few reports on GC hypersensi-
tivity in children exist although treatment with GCs is
particularly common in this age group [2,3].
Case presentation
We report the case of a 2-year-old boy who had been on a
well-tolerated long-term therapy of 100 μg inhaled fluti-
casone-dipropionate daily for frequently recurring epi-
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sodes of asthmatic exacerbations. He had intermittently
received prednisone suppositories (Rectodelt™) for acute
bronchopulmonary obstruction with no occurrence of
adverse events and had never been given any other gluco-
corticoid preparations. However, a few weeks before pres-
entation to our department, the patient was admitted to
another hospital because of severe bronchospasm. As nei-
ther inhalant bronchodilators nor 100 mg of rectally
applied prednisone resulted in any significant symptom
relief, 50 mg of prednisolone-21-hydrogen succinate
(PSH) (Solu-Decortin™) was administered intravenously.
Within a few minutes the boy developed generalized urti-
caria, facial angio-oedema, nausea and severe dyspnoea
requiring nasal oxygen supplementation. PSH medication
was interrupted and symptoms spontaneously resolved
within 30 minutes.
Upon presentation at our department of Paediatric Aller-
gology following a 3-week wash-out period, the boy was
in good health and we performed skin prick testing with a
panel of commercially available glucocorticoids accord-
ing to European Academy of Allergology and Clinical
Immunology guidelines [4]. Briefly, each drug was pre-
pared according to the manufacturer's recommendations
and the respective test reagent was diluted with sterile
physiologic saline solution. Epidermal testing was per-
formed with titrated dilutions (1:100 to 1:10) and, if neg-
ative, with the pure reagent. As the drug preparation under
investigation only contained the active ingredient (PSH)
no further skin prick tests with additives or other excipi-
ents were initiated.
Testing with PSH at a dilution of 1:10 elicited a positive
result (wheal diameter 6 mm), whereas no reactions were
observed to prednisone (Rectodelt™), betamethasone
(Celestamine N liquidum™) or dexamethasone (Fortecor-
tin™). While fluorescence enzyme immunoassay (FEIA)
analysis revealed no specific IgE antibodies against PSH,
CD63-based basophil activation testing with PSH induced
a significant increase in CD63-positive basophils as com-
pared with controls. In contrast, additional incubation of
basophils with prednisone, betamethasone and dexame-
thasone did not elicit any significant response.
In order to rule out any further clinically relevant hyper-
sensitivity reactions to other GCs and to provide the
patient with a safe GC-based emergency medication, we
performed an oral provocation test with betamethasone
and a titrated intravenous dexamethasone challenge. As
both drugs were tolerated without any complications,
they were recommended for further treatment.
Discussion
The precise pathomechanism of immediate-type hyper-
sensitivity to GCs remains unknown although the major-
ity of authors assume that it is possibly IgE-mediated [3].
While the relevant hapten has not been identified conclu-
sively, the cortisol metabolite glyoxal and the succinate
esters of hydrocortisone and methylprednisolone have
been pathogenetically implicated. These molecules are
thought to possess a particularly high allergenic potential
because of their increased water solubility and binding
affinity to serum proteins. The clinical relevance of these
findings is corroborated by the fact that hydrocortisone
and methylprednisolone succinate esters have been
reported to be the most common causative agents in
patients with GC hypersensitivity [5]. While our patient
revealed no cross-reactions with other GCs these have
been described previously in other affected individuals,
although no specific pattern of cross-reactivity has yet
been established [6]. Furthermore, sensitization to addi-
tives and other excipients, particularly carboxymethylcel-
lulose, has been observed in patients with GC
hypersensitivity [7]. However, in the case of our patient,
the applied culprit drug preparation did not contain any
additives or excipients according to the information sup-
plied by the manufacturer and the German national drug
manual. In addition, the other corticosteroid reagents
containing a set of additives were well tolerated during
oral provocation testing.
The clinical diagnosis of GC hypersensitivity is still prima-
rily based on a thorough medical history and skin prick
testing, while conventional in vitro diagnostic tools are
thought to have a rather low diagnostic yield. Specific IgE
antibodies to corticosteroids and their respective metabo-
lites have only rarely been described in patients with ana-
phylactic reactions and, as in our patient, a negative FEIA
result does not exclude glucocorticoid hypersensitivity.
Still, several investigators have recently suggested that the
basophil activation test (BAT) might be a helpful tool in
drug allergy research complementing routine tests, partic-
ularly if no proof of allergen-specific IgE is obtained by
routine methods or if no commercially available in vitro
assays exist [8]. To the best of our knowledge, this is the
first report of a positive BAT in a patient with GC hyper-
sensitivity, implying that this in vitro diagnostic tool may
enhance detection of GC-specific immediate-type sensiti-
zation in the future.
Conclusion
In a child with confirmed immediate-type hypersensitiv-
ity to GC, it is still not possible to predict which GC might
be tolerated by relying solely on clinical history or results
of skin and in vitro testing. Hence, incremental GC chal-
lenges under standardized clinical conditions remain nec-
essary in order to facilitate a patient-tailored emergency
treatment and to avoid severe reactions to GCs in these
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